Vise Technologies Inc. Buys 14,915 Shares of Novo Nordisk A/S $NVO

Vise Technologies Inc. increased its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 26.9% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 70,350 shares of the company’s stock after purchasing an additional 14,915 shares during the period. Vise Technologies Inc.’s holdings in Novo Nordisk A/S were worth $2,667,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in NVO. Scarborough Advisors LLC bought a new stake in Novo Nordisk A/S in the 1st quarter worth approximately $26,000. Root Financial Partners LLC purchased a new stake in Novo Nordisk A/S during the 3rd quarter valued at $32,000. Continuum Advisory LLC purchased a new stake in Novo Nordisk A/S during the 2nd quarter valued at $38,000. Latitude Advisors LLC bought a new position in shares of Novo Nordisk A/S during the 3rd quarter valued at $38,000. Finally, Markowski Investments bought a new position in shares of Novo Nordisk A/S during the 2nd quarter valued at $43,000. Institutional investors own 11.54% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on the company. HSBC restated a “hold” rating on shares of Novo Nordisk A/S in a research note on Thursday, September 10th. DZ Bank reiterated a “neutral” rating on shares of Novo Nordisk A/S in a research report on Thursday, August 6th. JPMorgan Chase & Co. reissued a “neutral” rating on shares of Novo Nordisk A/S in a report on Monday, September 21st. Citigroup reissued a “neutral” rating on shares of Novo Nordisk A/S in a research report on Friday, October 9th. Finally, Berenberg Bank restated a “neutral” rating on shares of Novo Nordisk A/S in a research note on Monday, September 21st. Five research analysts have rated the stock with a Buy rating, sixteen have assigned a Hold rating and five have issued a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $59.44.

More Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo beat analysts’ estimates for third-quarter earnings and revenue. Adjusted sales rose 4%, adjusted operating profit increased 27%, and obesity-drug sales climbed 22%. The company raised its full-year 2026 sales and operating-profit outlook. Reuters report on earnings and guidance
• Positive Sentiment: Wegovy pill sales exceeded Wall Street expectations, giving Novo a promising early foothold in the oral weight-loss drug market and helping drive the outlook upgrade. CEO Mike Doustdar said the launch had exceeded expectations. BioPharma Dive report on Wegovy pill sales
• Neutral Sentiment: Doustdar declined to provide 2027 guidance, leaving investors without a clear view of growth beyond this year. Novo’s CFO Karsten Munk Knudsen is also expected to leave the company. Article on earnings, outlook and 2027 guidance
• Negative Sentiment: Pricing pressure and weaker diabetes performance remain risks to growth, while impairment charges weighed on reported operating profit. Competition from Eli Lilly also remains a concern, especially as the oral obesity-drug market develops. Zacks analysis of earnings and risks

Novo Nordisk A/S Stock Up 5.0%

NVO opened at $42.21 on Thursday. Novo Nordisk A/S has a 1-year low of $35.12 and a 1-year high of $64.16. The firm’s 50 day simple moving average is $40.84 and its two-hundred day simple moving average is $44.07. The company has a current ratio of 0.87, a quick ratio of 0.66 and a debt-to-equity ratio of 0.55. The company has a market capitalization of $188.45 billion, a PE ratio of 10.32, a PEG ratio of 1.36 and a beta of 0.70.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings data on Tuesday, June 30th. The company reported $0.94 earnings per share (EPS) for the quarter. Novo Nordisk A/S had a return on equity of 58.61% and a net margin of 35.36%. The company had revenue of $11.98 billion during the quarter. As a group, equities analysts forecast that Novo Nordisk A/S will post 3.42 EPS for the current year.

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish pharmaceutical company headquartered in Bagsværd, Denmark. The company focuses on developing and manufacturing medicines and delivery systems for chronic diseases, with a primary emphasis on diabetes and obesity care.

Novo Nordisk offers a broad portfolio of insulin products, as well as glucagon-like peptide-1 (GLP-1) medicines used in diabetes management and weight treatment. Its well-known products include Ozempic and Rybelsus for type 2 diabetes, Wegovy for chronic weight management, and several modern and human insulin products.